trending Market Intelligence /marketintelligence/en/news-insights/trending/fp4zq4bav6zvsiatbqbvcq2 content esgSubNav
In This List

Callidus Capital CEO takes medical leave of absence

Podcast

Street Talk | Episode 94: Recessionary fears in ’22 overblown, Fed could overtighten

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Investment Banking Essentials Newsletter April Edition - 2022

Blog

Banking Essentials Newsletter April Edition - 2022


Callidus Capital CEO takes medical leave of absence

Callidus Capital Corp. Executive Chairman and CEO Newton Glassman will take a medical leave of absence, effective immediately.

He is undergoing further medical tests and examinations to confirm the extent and seriousness of his conditions. At minimum, Glassman is advised that he will require two significant operations on his lumbar spine, currently planned for the early fall 2018, followed by a period of intense rehabilitation and recuperation, according to a press release.

While investigating Glassman's lumbar spine, tests and examinations discovered significant issues with his cervical and thoracic spine that will require further analysis. The examinations also brought forward indications of a possible neurological disorder, which are also undergoing further analysis.

In view of this, his CEO duties have been re-assigned to the company's management team. Glassman intends to remain as executive chair and a director of Callidus. Furthermore, he has also committed to remain chair of the Callidus Credit Committee.

Glassman will remain in his role of managing partner of The Catalyst Capital Group Inc., which owns about 72% of the outstanding shares of Callidus.